Deputy Chairman and Senior Independent Director
Dr Andrew Heath was appointed to Oxford Biomedica's Board in January 2010 and became Deputy Chairman and Senior Independent Director in May 2011. Previously he was Chief Executive Officer of Protherics plc where he managed the company’s significant growth and eventual acquisition by BTG for £220 million. Previously, he held senior positions at Astra AB and Astra USA, including Vice President Marketing & Sales, and at Glaxo Sweden as Associate Medical Director. He is currently Chairman of Shield Therapeutics plc, and a non-executive director of Novacyt SA and IHT Partners, LLC. He was previously a director of the UK BioIndustry Association.